- Trial phase
- Phase 3
- Time to market
- If Phase 3 succeeds, potential regulatory filing would be around 2029-2030 based on the estimated December 2029 primary completion date of the pivotal trial.
- Why 3/10
- No hard dated binary catalyst (PDUFA or pivotal readout) is scheduled within the next ~12 months. The Phase 3 AMUR-Lung-01 trial began recruiting in September 2026 with estimated primary completion in December 2029. For a large-cap diversified pharma like AbbVie, this single mid-stage asset represents a small fraction of enterprise value.
The next hard catalyst for ABBV-1480 is the Phase 3 AMUR-Lung-01 (NCT07756645) data readout, but with estimated primary completion in December 2029, no binary event is expected within the next 12 months. Watch for interim analysis announcements, expansion into additional solid tumor indications, and any early efficacy signals from the ongoing Phase 3 enrollment. For a company of AbbVie's size, this is one of many pipeline assets and not a near-term value driver.
Price Chart
Executive Summary
ABBV-1480 (RC148) is an investigational PD-1/VEGF bispecific antibody being developed by AbbVie (ABBV) under a January 2026 licensing deal with RemeGen that included a $650M upfront payment and up to $4.95B in milestones. Phase 1b data presented at WCLC 2026 showed a 90% objective response rate in first-line squamous NSCLC when combined with chemotherapy, and ESMO 2026 data showed 61.9% ORR as monotherapy in PD-L1-positive NSCLC. A global Phase 3 trial (AMUR-Lung-01, NCT07756645) comparing ABBV-1480 plus chemo against Keytruda plus chemo in 940 patients began recruiting in September 2026 with estimated completion in December 2029. For AbbVie, a $295B+ market cap diversified pharma, ABBV-1480 is one of many pipeline assets with no near-term binary catalyst.
How It Works
ABBV-1480 is a bispecific antibody, a single engineered molecule designed to hit two targets at once. It blocks PD-1 (a brake on immune cells that tumors exploit to hide) and VEGF (a protein tumors use to grow blood vessels for their own supply). By disabling both pathways simultaneously, the drug aims to let the immune system attack the tumor while cutting off its blood supply. Its design uses a VEGF-triggered enrichment mechanism that may concentrate the drug in the tumor area and reduce side effects compared to giving two separate drugs.
Trial Status
The global Phase 3 AMUR-Lung-01 trial (NCT07756645) began recruiting in September 2026, comparing ABBV-1480 plus platinum-based chemotherapy against pembrolizumab (Keytruda) plus chemotherapy as first-line treatment for advanced/metastatic non-small cell lung cancer, targeting 940 participants. Phase 1b data in 1L NSCLC and Phase 1 monotherapy data in PD-L1-positive NSCLC were presented at WCLC 2026 and ESMO 2026, respectively. A combination study with AbbVie's c-Met ADC Temab-A in NSCLC (NCT07874282) has also been initiated.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 AMUR-Lung-01 interim analysis (no date announced; trial estimated to complete Dec 2029)
- Expansion into additional solid tumor indications beyond NSCLC
- Potential partnership or combination study updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report